Reston, Virginia—New research published ahead of print in The Journal of Nuclear Medicine is highlighting how molecular imaging can reveal disease biology earlier, predict treatment response more precisely, and potentially distinguish infection from sterile inflammation. Across five studies involving Alzheimer disease, metastatic prostate cancer, brain imaging, and bacterial infection, researchers used positron emission tomography (PET), single-photon emission computed tomography/computed tomography (SPECT/CT), and magnetic resonance imaging (MRI) to move beyond simply locating disease. Their findings suggest that the information contained in an image may help identify biological risk, guide treatment decisions, and improve the accuracy of personalized medicine.
One study examined a region of amyloid PET results that is often treated as diagnostically uncertain: the intermediate range between clearly low and clearly elevated amyloid deposition. Researchers analyzed 512 individuals and found that people in this middle range were not necessarily biologically normal. Instead, intermediate amyloid uptake was associated with evidence of tau pathology and measurable cognitive decline. Amyloid plaques and tau tangles are two of the defining biological features of Alzheimer disease, but they do not appear at precisely the same time or progress at identical rates in every person. The findings suggest that intermediate amyloid burden may represent an active transition point in the disease process rather than an unimportant gray zone.
Amyloid PET uses radiolabeled compounds that bind to amyloid plaques, allowing clinicians and researchers to visualize the distribution of abnormal protein deposits in the living brain. In routine interpretation, scans may be categorized as positive or negative, but a binary approach can obscure gradual biological changes. The new results indicate that quantitative or semiquantitative analysis of amyloid signal may identify individuals who are already showing downstream effects, even when their plaque burden has not reached the level traditionally considered definitively abnormal. Because tau accumulation is more closely associated with neuronal injury and clinical symptoms than amyloid alone, the link between intermediate amyloid uptake, tau pathology, and cognition could help improve the timing of prevention trials and early interventions.
The prostate cancer studies focused on a different application of molecular imaging: determining whether treatment is working before conventional clinical measures provide a clear answer. One investigation followed 158 men with metastatic castration-resistant prostate cancer receiving lutetium-177–labeled prostate-specific membrane antigen therapy, known as ^177Lu-PSMA-617. This radioligand therapy uses a radioactive isotope attached to a molecule that targets PSMA, a protein expressed at high levels on many prostate cancer cells. After the compound binds to tumor tissue, the beta radiation emitted by lutetium-177 delivers lethal energy over a limited distance, potentially damaging cancer cells while reducing exposure to surrounding organs.
Researchers evaluated same-day posttherapy SPECT/CT scans after treatment and found that early imaging changes were associated with overall survival. Patients whose scans showed an imaging response after two treatment cycles lived longer than those without such a response. High tumor burden and a lack of prostate-specific antigen, or PSA, response were associated with poorer outcomes. SPECT/CT combines functional imaging with anatomical localization: SPECT detects the distribution of the radiolabeled treatment, while CT shows where the disease is located and how extensive it is. Because the scan is performed after therapy, it can provide both a map of treated tumor and an indication of how much radiopharmaceutical has reached the cancer.
A separate study assessed whether fluorine-18 fluorodeoxyglucose, or ^18F-FDG, could add prognostic information to PSMA PET before ^177Lu-PSMA-617 treatment. The analysis included 99 men with metastatic castration-resistant prostate cancer. PSMA PET uses a radiotracer designed to bind PSMA, while FDG PET measures glucose metabolism. Cancer cells often consume glucose at elevated rates, causing them to accumulate FDG, although the intensity of this signal can vary according to tumor biology. The investigators found that PSMA PET measurements strongly separated patients according to expected survival, but FDG-derived tumor burden supplied additional risk information, especially among patients with a high overall metabolic tumor burden.
The combination of the two tracers may be important because PSMA expression and glucose metabolism do not always tell the same biological story. A tumor can show strong PSMA uptake and therefore appear suitable for targeted radioligand therapy, yet also contain regions with aggressive metabolic behavior. Conversely, areas with low PSMA expression may be less effectively targeted by ^177Lu-PSMA-617 even if they are metabolically active on FDG PET. Using both imaging approaches could help physicians recognize disease heterogeneity, identify patients who may need additional or alternative treatment, and interpret treatment risk more realistically before therapy begins. The findings do not establish a new treatment strategy by themselves, but they support a more detailed imaging-based approach to patient selection and prognosis.
Another study addressed a technical challenge in Alzheimer disease imaging: the possibility that brain tissue composition can influence the signal attributed to amyloid. Researchers examined 114 participants using amyloid PET together with MRI measurements of intracortical myelin. Myelin is the lipid-rich insulating material that surrounds many nerve fibers and helps electrical signals travel efficiently through the brain. Intracortical myelin is located within the cerebral cortex, the thin outer layer involved in memory, perception, language, and decision-making. Because the physical properties of myelin can affect the behavior of imaging signals, variations in myelin may influence PET measurements even when amyloid levels are unchanged.
The investigators found that the MRI-derived myelin water fraction independently predicted amyloid PET signal and improved statistical models by approximately 6 percent. Myelin water fraction estimates the proportion of water associated with myelin layers and is used as an indirect marker of myelin content. In PET, the measured signal depends not only on tracer binding but also on tissue structure, blood flow, attenuation, and other biological factors. If myelin contributes to regional differences in apparent amyloid uptake, incorporating MRI-based tissue information could make quantification more precise. This may be particularly relevant when researchers compare subtle changes over time or evaluate people whose amyloid levels fall near a diagnostic threshold.
The fifth study explored a strategy for imaging Pseudomonas aeruginosa, a bacterium that can cause serious lung, bloodstream, wound, and hospital-acquired infections. The researchers developed a PET tracer cocktail made from three gallium-68–labeled pyoverdines. Pyoverdines are fluorescent iron-scavenging molecules, or siderophores, produced by P. aeruginosa to capture iron from the surrounding environment. By labeling these bacterial molecules with gallium-68, the investigators created imaging agents that exploit a microbial nutrient-acquisition pathway rather than relying only on nonspecific inflammation.
In animal experiments, the tracer cocktail detected multiple P. aeruginosa strains while showing little or no uptake in sterile inflammation, other pathogens, or inactive bacteria. That specificity is potentially significant because current imaging methods often reveal that inflammation is present without identifying its cause. Infection and sterile inflammation can look similar on anatomical scans, yet they require very different treatments. A pathogen-directed PET signal could help clinicians distinguish active bacterial infection from immune reaction, identify disease earlier, and avoid unnecessary antibiotics. The work remains preclinical, and further studies will be needed to establish safety, optimal dosing, performance in humans, and whether the approach can reliably detect infections in complex clinical settings.
Together, the studies illustrate the expanding role of nuclear medicine as a source of biological information rather than a simple diagnostic photograph. Amyloid and tau-related imaging may clarify the earliest stages of neurodegeneration; MRI may correct for tissue factors that complicate PET interpretation; and combined PSMA, FDG, and posttherapy SPECT/CT may provide a more complete picture of prostate cancer behavior and treatment response. Meanwhile, pyoverdine-based imaging demonstrates how radiotracers can be designed around the chemistry of a specific pathogen. These approaches reflect a broader shift toward theranostics and precision imaging, in which the same molecular features used to detect disease can also help determine prognosis or deliver treatment.
The research was published ahead of print by The Journal of Nuclear Medicine, the journal of the Society of Nuclear Medicine and Molecular Imaging. The studies reinforce the idea that the most valuable scan may be one that answers a biological question: whether a disease process has begun, whether a tumor is responding, whether apparently similar lesions carry different risks, or whether inflammation is caused by living bacteria. As molecular imaging technologies become more quantitative and are combined with complementary modalities, researchers hope they will support earlier diagnosis, better treatment selection, and more individualized care.
Subject of Research: Molecular imaging, Alzheimer disease, prostate cancer theranostics, amyloid PET quantification, and pathogen-specific infection imaging.
Article Title: “Intermediate Amyloid PET Levels Linked to Tau Pathology and Cognitive Decline”; “Early SPECT/CT Response Predicts Survival in PSMA-Positive Prostate Cancer”; “FDG PET Adds Prognostic Information in PSMA-Targeted Prostate Cancer Therapy”; “MRI Myelin Measures May Improve Amyloid PET Quantification”; and “PET Tracer Cocktail Targets Pseudomonas aeruginosa Infections.”
News Publication Date: August 14, 2026.
Web References: The Journal of Nuclear Medicine: https://jnm.snmjournals.org/; Society of Nuclear Medicine and Molecular Imaging Media Center: http://www.snmmi.org/Media.aspx
References: https://doi.org/10.2967/jnumed.126.272655; https://doi.org/10.2967/jnumed.126.272651; https://doi.org/10.2967/jnumed.126.273113; https://doi.org/10.2967/jnumed.126.272591; https://doi.org/10.2967/jnumed.125.271909
Keywords: Molecular imaging, nuclear medicine, positron emission tomography, PET, SPECT/CT, Alzheimer disease, amyloid, tau pathology, myelin, prostate cancer, PSMA, ^177Lu-PSMA-617, FDG PET, theranostics, Pseudomonas aeruginosa, pyoverdine, infection imaging, personalized medicine.
Tags: advancements in nuclear medicine for infectious disease diagnosisbiological risk assessment through advanced imaging techniquesdistinguishing infection from sterile inflammation with nuclear imagingearly detection of Alzheimer’s disease using amyloid PETimaging biomarkers in metastatic prostate cancerinterpreting intermediate amyloid levels in Alzheimer’smolecular imaging in disease diagnosisMRI for brain disease detectionpersonalized medicine guided by nuclear imaging biomarkersPET and SPECT/CT in cancer stagingpredicting treatment response with molecular imagingrole of tau pathology in Alzheimer’s disease progression
